Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment
Authors:
Open Access
- 1 May 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 97 (9) , 2830-2838
Abstract
Treatment of different human leukemia cell variants with the anthracycline adriamycin was associated with a rapid activation of the proteasome. Thus, proliferating U937, TUR, and retrodifferentiated U937 cells exhibited a 4.3-fold, 5.8-fold, and 4.3-fold proteasome activation within 15 minutes after adriamycin treatment, respectively. In contrast, little if any proteasome activation was detectable in a growth-arrested differentiated U937 population following adriamycin treatment. Further analysis of this mechanism revealed a significant reduction of adriamycin-induced proteasome activity after inhibition of poly(ADP-ribose) polymerase (PARP) by 3-aminobenzamide (3-ABA) in the proliferating leukemic cell types. These findings suggested that PARP is involved in the regulation of drug-induced proteasome activation. Indeed, anti-PARP immunoprecipitation experiments of adriamycin-treated cells revealed increasing levels of coprecipitated, enzymatically active proteasome particularly in the proliferating cell variants in contrast to the differentiated U937 cells, with a maximum after 15 minutes, and sensitivity to PARP inhibition by 3-ABA. The specific role of the PARP was investigated in U937 and TUR cell clones stably transfected with a constitutively active antisense PARP (asPARP) vector. Thus, asPARP-TUR cells developed a 25-fold increased sensitivity to adriamycin treatment. Furthermore, we investigated leukemic blasts isolated from acute myelogenous leukemia patients and obtained a similarly enhanced proteasome activity after adriamycin treatment, which was dependent on the PARP and thus could be coprecipitated with anti-PARP antibodies. Transient transfection of leukemic blasts with the asPARP vector significantly reduced the adriamycin-induced proteasome activation. These data suggest that the PARP-associated nuclear proteasome activation represents a potential target within chemotherapeutic defense mechanisms developed by leukemia cells.Keywords
This publication has 44 references indexed in Scilit:
- Functional Interaction of Poly(ADP-ribose) with the 20S Proteasome in VitroBiochemical and Biophysical Research Communications, 1999
- Signaling Defect in the Activation of Caspase-3 and PKCδ in Human TUR Leukemia Cells Is Associated with Resistance to ApoptosisExperimental Cell Research, 1999
- Poly(ADP-ribosyl)ation of Histone H1 Correlates with Internucleosomal DNA Fragmentation during ApoptosisJournal of Biological Chemistry, 1996
- Dependence of nucleic acid degradation on in situ free-radical production by AdriamycinBiochemistry, 1993
- Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cellsCarcinogenesis, 1993
- Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.Environmental Health Perspectives, 1991
- The frequency of long‐term remission in patients with acute myelogenous leukaemia treated with conventional maintenance chemotherapy: a study of 760 patients with a minimal follow‐up time of 6 yearsBritish Journal of Haematology, 1989
- A simple technique for quantitation of low levels of DNA damage in individual cellsExperimental Cell Research, 1988
- Effect of Adriamycin and Hyperthermia on the Sedimentation of Nucleoids from L1210 CellsInternational Journal of Radiation Biology, 1988
- Prevention of adriamycin-induced interphase death by 3-aminobenzamide and nicotinamide in a human promyelocytic leukemia cell lineBiochemical and Biophysical Research Communications, 1987